Core Insights - The increasing societal focus on blood health and support for acute myeloid leukemia (AML) patients is highlighted, with a call for public education on prevention, diagnosis, treatment, and recovery [1][2] - The treatment of AML is evolving towards precision and diversification, with targeted therapies marking the entry into a "precision era" [1] - The application of second-generation FLT3 inhibitors is significantly improving the prognosis for patients with FLT3 mutations, extending median overall survival to 9.3 months while reducing side effects [1] - The widespread use of minimal residual disease (MRD) monitoring technology is aiding in the precise detection of residual cancer cells, allowing for timely treatment adjustments and reduced relapse risk [1] Treatment Recommendations - It is advised that families with a leukemia diagnosis engage actively with healthcare providers to choose appropriate medical institutions based on economic conditions, accessibility, resource allocation, and treatment expectations [2] - The collaboration between the medical community, society, and AML patients' families is expected to enhance the comprehensive management system for AML, making "precision diagnosis and warm recovery" more accessible to families [2]